Blood-Based Ageing Clock Shows Promise as a Clinical Tool
A groundbreaking study has developed a blood-based ageing clock capable of predicting biological age and providing insights into the ageing process. Read on to learn more!
Related Articles
Dr Salani on Managing Mirvetuximab Soravtansine–Associated Ocular Toxicities in Ovarian Cancer
Ritu Salani, MD, MBA, discusses the management of ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.
Welcome! You are invited to join a webinar: [Live Webinar] – Optimising the management of HR+ HER2- metastatic breast cancer. After registering, you will receive a confirmation email about joining the webinar.
Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss…
cfDNA screening for fetal aneuploidy facilitates maternal cancer detection
Nature Reviews Clinical Oncology – cfDNA screening for fetal aneuploidy facilitates maternal cancer detection
Welcome! You are invited to join a webinar: Skin VJSessions: Therapeutic Advances in PD-1 Refractory Skin Cancer. After registering, you will receive a confirmation email about joining the webinar.
Therapeutic options for PD-1 refractory skin cancer 3 Jan – 6PM BST | 1PM EDT | 10AM PDT Allison Betof Warner, Omid Hamid, Inderjit Mehmi…
The role of hydroxyurea as a disease-modifying agent in SCD & challenges in optimizing its efficacy
Susan Creary, MD, Nationwide Children’s Hospital, Columbus, OH, comments on the role of hydroxyurea as a disease-modifying agent for sickle cell disease (SCD), highlighting its…
Transforming Lives Through Research
Saving more lives through groundbreaking research – and improving the lives of all people facing cancer – is the mission of the Robert H. Lurie…
Dr D’Angelo on the Significance of Lete-Cel Treatment Across Sarcoma Subtypes
Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.
Nilotinib, Dasatinib Yield Similar Outcomes in CML – Oncology Nurse Advisor
Researchers sought to assess whether nilotinib and dasatinib would have similar efficacy in patients with CML in chronic phase.
Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer
Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.